Trials / Completed
CompletedNCT00759200
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa-naïve Patients With Genotype 2/3 Chronic Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 525 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alb-interferon alfa 2b | 900 mcg every 4 weeks |
| DRUG | alb-interferon alfa 2b | 1200 mcg every 4 weeks |
| DRUG | alb-interferon alfa 2b | 1500 mcg every 4 weeks |
| DRUG | alb-interferon alfa 2b | 1800 mcg every 4 weeks |
| DRUG | peg-interferon | Peg-interferon alfa 2a: 180 mcg 1x per wk. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2008-09-25
- Last updated
- 2016-11-16
Locations
55 sites across 12 countries: Australia, Canada, France, Germany, Greece, India, Italy, Poland, Spain, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00759200. Inclusion in this directory is not an endorsement.